ES2431963T3 - Partícula viral adyuvante - Google Patents
Partícula viral adyuvante Download PDFInfo
- Publication number
- ES2431963T3 ES2431963T3 ES03739913T ES03739913T ES2431963T3 ES 2431963 T3 ES2431963 T3 ES 2431963T3 ES 03739913 T ES03739913 T ES 03739913T ES 03739913 T ES03739913 T ES 03739913T ES 2431963 T3 ES2431963 T3 ES 2431963T3
- Authority
- ES
- Spain
- Prior art keywords
- papmv
- virus
- particle
- protein
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002245 particle Substances 0.000 title claims abstract description 98
- 239000002671 adjuvant Substances 0.000 title claims abstract description 40
- 230000003612 virological effect Effects 0.000 title description 16
- 241000709995 Papaya mosaic virus Species 0.000 claims abstract description 154
- 108091007433 antigens Proteins 0.000 claims abstract description 68
- 102000036639 antigens Human genes 0.000 claims abstract description 68
- 239000000427 antigen Substances 0.000 claims abstract description 67
- 241000700605 Viruses Species 0.000 claims abstract description 53
- 230000028993 immune response Effects 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 241001465754 Metazoa Species 0.000 claims abstract description 25
- 229960005486 vaccine Drugs 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract description 21
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 20
- 101710188315 Protein X Proteins 0.000 claims abstract description 20
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 15
- 108700030444 papaya mosiac virus coat Proteins 0.000 claims abstract 4
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 22
- 108020001507 fusion proteins Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 20
- 241000711549 Hepacivirus C Species 0.000 claims description 17
- 230000004927 fusion Effects 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002255 vaccination Methods 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 6
- 230000005923 long-lasting effect Effects 0.000 claims description 6
- 230000015654 memory Effects 0.000 claims description 5
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 23
- 108010078791 Carrier Proteins Proteins 0.000 description 16
- 239000013256 coordination polymer Substances 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 210000000987 immune system Anatomy 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000002434 immunopotentiative effect Effects 0.000 description 8
- 241001112090 Pseudovirus Species 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 108010013381 Porins Proteins 0.000 description 5
- 102000017033 Porins Human genes 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000000091 immunopotentiator Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000723655 Cowpea mosaic virus Species 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 241000710007 Potexvirus Species 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 241000287433 Turdus Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000006041 cell recruitment Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000724328 Alfalfa mosaic virus Species 0.000 description 1
- 101100042610 Arabidopsis thaliana SIGB gene Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000219173 Carica Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700008783 Hepatitis C virus E1 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 101150117326 sigA gene Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/26011—Flexiviridae
- C12N2770/26023—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39365902P | 2002-07-05 | 2002-07-05 | |
| US393659P | 2002-07-05 | ||
| PCT/CA2003/000985 WO2004004761A2 (en) | 2002-07-05 | 2003-06-30 | Adjuvant viral particle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2431963T3 true ES2431963T3 (es) | 2013-11-28 |
Family
ID=30115621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03739913T Expired - Lifetime ES2431963T3 (es) | 2002-07-05 | 2003-06-30 | Partícula viral adyuvante |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7641896B2 (https=) |
| EP (2) | EP2272525A3 (https=) |
| JP (1) | JP4953570B2 (https=) |
| KR (1) | KR20050044886A (https=) |
| CN (1) | CN1665528B (https=) |
| AU (1) | AU2003281246A1 (https=) |
| BR (1) | BR0312474A (https=) |
| CA (1) | CA2434000C (https=) |
| DK (1) | DK1523329T3 (https=) |
| ES (1) | ES2431963T3 (https=) |
| MX (1) | MXPA05000287A (https=) |
| NO (1) | NO20050396L (https=) |
| PT (1) | PT1523329E (https=) |
| WO (1) | WO2004004761A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
| JP4953570B2 (ja) * | 2002-07-05 | 2012-06-13 | フォリア バイオテック インコーポレイテッド | アジュバントウィルス粒子 |
| CA2580208A1 (en) * | 2004-09-21 | 2006-03-30 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| NZ554386A (en) | 2004-10-25 | 2009-12-24 | Cytos Biotechnology Ag | Gastric inhibtory polypeptide (GIP) antigen arrays with VLPs and uses thereof |
| KR100688522B1 (ko) * | 2005-01-18 | 2007-03-02 | 삼성전자주식회사 | 영상데이터 압축기 및 압축방법 |
| WO2007053188A2 (en) | 2005-06-01 | 2007-05-10 | Dow Global Technologies, Inc. | Production of multivalent virus like particles |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| WO2012048430A1 (en) * | 2010-10-14 | 2012-04-19 | Folia Biotech Inc. | Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof |
| CA2669345A1 (en) | 2006-11-15 | 2008-05-22 | Folia Biotech Inc. | Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof |
| DK2069503T3 (da) * | 2006-11-15 | 2016-02-15 | Folia Biotech Inc | Papayamosaikvirus-baserede vacciner mod influenza |
| WO2008089569A1 (en) * | 2007-01-26 | 2008-07-31 | Folia Biotech Inc. | Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens |
| WO2009014782A2 (en) * | 2007-04-27 | 2009-01-29 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
| US20110104191A1 (en) * | 2007-09-11 | 2011-05-05 | Universite Laval | Malva mosaic virus and virus-like particles and uses thereof |
| CA2728374A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
| CA2742288A1 (en) * | 2008-07-30 | 2010-02-04 | Folia Biotech Inc. | Multivalent vaccines based on papaya mosaic virus and uses thereof |
| WO2012078069A1 (en) * | 2010-12-09 | 2012-06-14 | Iosif Grigorievich Atabekov | Spherical nano- and microparticles derived from plant viruses for the display of foreign proteins or epitopes |
| US20140154288A1 (en) | 2011-05-13 | 2014-06-05 | Folia Biotech Inc. | Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response |
| CN103687617B (zh) | 2011-06-09 | 2017-09-15 | 碧欧美公司 | 作为过敏症疫苗的肽载体融合蛋白 |
| CN104395346A (zh) * | 2012-04-02 | 2015-03-04 | 弗利亚生物技术公司 | 重组木瓜花叶病毒外壳蛋白及其在流感疫苗中的应用 |
| JP2016531927A (ja) * | 2013-09-19 | 2016-10-13 | フォリア バイオテック インコーポレイテッド | 癌治療でのパパイヤモザイクウイルス及びウイルス様粒子 |
| WO2016176558A1 (en) * | 2015-04-30 | 2016-11-03 | The Regents Of The University Of California | Adjuvant particles comprising adenosine receptor antagonists |
| CA3176880A1 (en) * | 2020-03-31 | 2021-10-07 | Mediphage Bioceuticals, Inc. | Vectors for producing virus-like particles and uses thereof |
| WO2022152939A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL79880A0 (en) | 1985-08-29 | 1986-11-30 | Inst Medical W & E Hall | Recombinant virus |
| US5977438A (en) * | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
| DE4006630A1 (de) | 1990-03-03 | 1991-09-12 | Behringwerke Ag | Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung |
| DE69128898T2 (de) * | 1990-08-15 | 1998-05-28 | Therion Biolog Corp | Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel |
| US5443969A (en) * | 1992-10-29 | 1995-08-22 | Rutgers University | RNA packaging system |
| GB9414118D0 (en) * | 1994-07-13 | 1994-08-31 | Axis Genetics Ltd | Modified plant viruses as vectors of heterologous peptides |
| AU702802B2 (en) | 1994-10-18 | 1999-03-04 | Scottish Crop Research Institute | Method of producing a chimeric protein |
| GB9607899D0 (en) | 1996-04-17 | 1996-06-19 | Scottish Crop Research Inst | Virus-like particle |
| US6042832A (en) | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
| EP0980257A1 (en) * | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US6228368B1 (en) | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| DE19752855C2 (de) * | 1997-11-28 | 2003-04-03 | Bundesrepublik Deutschland Let | Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer |
| GB9806666D0 (en) | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
| IL140918A0 (en) | 1998-07-27 | 2002-02-10 | Genentech Inc | Improved transformation efficiency in phage display through modification of a coat protein |
| FR2786773B1 (fr) | 1998-12-03 | 2002-03-08 | Univ Paris Curie | Proteines d'enveloppe, methodes et utilisations |
| EA004497B1 (ru) * | 1998-12-04 | 2004-04-29 | Байоджен, Инк. | Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов |
| DE19904800C1 (de) | 1999-02-05 | 2001-02-08 | Eberhard Hildt | Partikel zur Gentherapie |
| GB9921337D0 (en) * | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
| GB9924351D0 (en) * | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
| GB9924352D0 (en) | 1999-10-14 | 1999-12-15 | Hellendoorn Koen | Methods,compositions and applications relating to the generation of novel plant viral particles |
| US6730306B1 (en) | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
| AUPQ661600A0 (en) | 2000-03-31 | 2000-05-04 | Macfarlane Burnet Centre For Medical Research Limited, The | A nucleic acid construct and methods related thereto |
| IT1317046B1 (it) * | 2000-06-16 | 2003-05-26 | Ist Superiore Sanita | Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni |
| AU2001270164A1 (en) | 2000-06-26 | 2002-01-08 | The United States Of America As Represented By The Secretary Of Agriculture | Production of vaccines using transgenic plants |
| ES2317910T3 (es) | 2000-07-06 | 2009-05-01 | Georgetown University | Formas (fijas) estables e proteinas de capside l1 virales, proteinas de fusion y sus utilizaciones. |
| GB0028319D0 (en) * | 2000-11-20 | 2001-01-03 | Univ Southampton | Materials and methods relating to fusion proteins for inducing an immune response |
| ITRM20010332A1 (it) * | 2001-06-11 | 2002-12-11 | Ist Superiore Sanita | Vaccini a subunita' e procedimenti per la loro produzione. |
| JP4953570B2 (ja) * | 2002-07-05 | 2012-06-13 | フォリア バイオテック インコーポレイテッド | アジュバントウィルス粒子 |
| US8101189B2 (en) * | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
-
2003
- 2003-06-30 JP JP2004518318A patent/JP4953570B2/ja not_active Expired - Fee Related
- 2003-06-30 ES ES03739913T patent/ES2431963T3/es not_active Expired - Lifetime
- 2003-06-30 WO PCT/CA2003/000985 patent/WO2004004761A2/en not_active Ceased
- 2003-06-30 EP EP10179379A patent/EP2272525A3/en not_active Withdrawn
- 2003-06-30 PT PT37399136T patent/PT1523329E/pt unknown
- 2003-06-30 DK DK03739913.6T patent/DK1523329T3/da active
- 2003-06-30 KR KR1020057000114A patent/KR20050044886A/ko not_active Withdrawn
- 2003-06-30 CA CA2434000A patent/CA2434000C/en not_active Expired - Fee Related
- 2003-06-30 BR BR0312474-6A patent/BR0312474A/pt not_active Application Discontinuation
- 2003-06-30 MX MXPA05000287A patent/MXPA05000287A/es active IP Right Grant
- 2003-06-30 EP EP03739913.6A patent/EP1523329B1/en not_active Expired - Lifetime
- 2003-06-30 CN CN03815935XA patent/CN1665528B/zh not_active Expired - Fee Related
- 2003-06-30 AU AU2003281246A patent/AU2003281246A1/en not_active Abandoned
- 2003-07-01 US US10/609,417 patent/US7641896B2/en not_active Expired - Fee Related
-
2005
- 2005-01-25 NO NO20050396A patent/NO20050396L/no not_active Application Discontinuation
-
2009
- 2009-04-03 US US12/384,476 patent/US8282940B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1523329B1 (en) | 2013-07-24 |
| AU2003281246A1 (en) | 2004-01-23 |
| JP4953570B2 (ja) | 2012-06-13 |
| WO2004004761A3 (en) | 2004-05-06 |
| MXPA05000287A (es) | 2005-09-08 |
| US7641896B2 (en) | 2010-01-05 |
| DK1523329T3 (da) | 2013-10-14 |
| JP2006504644A (ja) | 2006-02-09 |
| KR20050044886A (ko) | 2005-05-13 |
| PT1523329E (pt) | 2013-10-08 |
| HK1075214A1 (en) | 2005-12-09 |
| CN1665528A (zh) | 2005-09-07 |
| CA2434000A1 (en) | 2004-01-05 |
| WO2004004761A2 (en) | 2004-01-15 |
| BR0312474A (pt) | 2005-04-26 |
| US20090280145A1 (en) | 2009-11-12 |
| EP1523329A2 (en) | 2005-04-20 |
| CN1665528B (zh) | 2013-05-15 |
| CA2434000C (en) | 2012-07-17 |
| US8282940B2 (en) | 2012-10-09 |
| EP2272525A3 (en) | 2011-11-16 |
| US20050048082A1 (en) | 2005-03-03 |
| NO20050396L (no) | 2005-01-25 |
| EP2272525A2 (en) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2431963T3 (es) | Partícula viral adyuvante | |
| Cui et al. | Flagellin as a vaccine adjuvant | |
| ES2139879T5 (es) | Adyuvante de la mucosa no toxico. | |
| Cui | DNA vaccine | |
| Brennan et al. | Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus | |
| US9339535B2 (en) | Vaccines and immunopotentiating compositions and methods for making and using them | |
| CN104395336B (zh) | 以计算方式优化的h5n1和h1n1流感病毒的广泛反应性抗原 | |
| ES2533345T3 (es) | Diferentes serotipos del virus de la estomatitis vesicular como vectores de expresión para regímenes de inmunización | |
| US7927833B2 (en) | Composition and method for enhancing immune response | |
| Narayanan et al. | Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy | |
| ES2924914T3 (es) | Vacuna contra rinovirus humano | |
| Kammer et al. | Rabies vaccines: from the past to the 21st century | |
| ES2648337T3 (es) | Uso del PACAP como adyuvante molecular para vacunas | |
| Arnon et al. | Peptide-based synthetic recombinant vaccines with anti-viral efficacy | |
| HK1151730A (en) | Adjuvant viral particle | |
| HK1075214B (en) | Adjuvant viral particle | |
| ES2328140T3 (es) | Hsp60 del arthrobacter. | |
| KR102946895B1 (ko) | SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도 | |
| US20230100362A1 (en) | Conjugate Vaccines Containing Hydrazine-PEG-Hydrazine Linkers | |
| WO2008015309A1 (es) | Construcción peptídica dendrimérica para la prevención de la fiebre aftosa en animales. | |
| ES2358733T3 (es) | Vacuna derivada de levadura contra ipnv. | |
| CN113876941A (zh) | 一种新的快速高效低价的人工合成疫苗的设计和应用 | |
| Zaher et al. | The role of DNA vaccine as a control measure for viral disease | |
| Ben-Yedidia | A peptide-based vaccine against influenza | |
| Falzarano | Edible vaccines: immunological response to hepatitis B virus nucleocapsid derived from transgenic plants |